Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
复制标题
特邀观点“唑尼沙胺治疗路易体痴呆患者帕金森病的长期疗效和安全性：3 期随机对照试验的开放标签扩展”。
DOI：
10.1016/j.jagp.2021.07.017
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Pontone,GregoryM
中科院分区：
文献类型：
--
作者：
Hinkle,JaredT;Pontone,GregoryM
路易体痴呆（DLB）的管理对患者和护理人员来说是一个复杂的挑战。该疾病的特点是认知状态波动，伴有嗜睡、神志不清和注意力不集中。DLB经常伴有令人不安的妄想和视觉幻觉，以及帕金森病的运动综合征。与特发性帕金森病（PD）一样，DLB中的帕金森病是由黑质中多巴胺神经元的退化引起的，这会耗尽多巴胺的运动纹状体。PD和DLB具有路易小体的病理特征，即含有α -突触核蛋白的蛋白包涵体，提示病理生物学上有重叠。不管怎样，多巴胺替代品——比如左旋多巴——是两种疾病帕金森症状控制的关键工具。与PD相比，DLB的帕金森病对左旋多巴的反应较弱，其疗效下降速度比PD更快（1,2）。多巴胺类药物也可能恶化某些©Elsevier出版的2021。这份手稿是在爱思唯尔用户许可https://www下提供的。爱思唯尔。com/open-access/userlicense/1.0/
The management of dementia with Lewy bodies (DLB) is a complex challenge for patients and caregivers. The disease is marked by fluctuating cognitive status with periods of lethargy, confusion, and inattentiveness. DLB is frequently complicated by disturbing delusions and visual hallucinations, as well as the motor syndrome of parkinsonism. As in idiopathic Parkinson’s disease (PD), parkinsonism in DLB is caused by the degeneration of dopamine neurons in the substantia nigra, which depletes the motor striatum of dopamine. PD and DLB share the pathological hallmark of Lewy bodies, proteinaceous inclusions containing the protein alpha-synuclein, suggesting pathobiological overlap. Regardless, dopamine replacement—such as levodopa—is a key tool for symptomatic control of parkinsonism in both diseases. Compared to that of PD, the parkinsonism of DLB can be less responsive to levodopa and its efficacy wanes more quickly than in PD (1, 2). Dopaminergic medications may also worsen certain© 2021 published by Elsevier. This manuscript is made available under the Elsevier user license https://www. elsevier. com/open-access/userlicense/1.0/